Zacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold
Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
CYTX has been the topic of a number of other research reports. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday. Finally, B. Riley reissued a “buy” rating and set a $2.30 price objective on shares of Cytori Therapeutics in a report on Monday, May 15th.
Cytori Therapeutics (NASDAQ CYTX) traded up 5.41% during trading on Wednesday, reaching $1.17. The company’s stock had a trading volume of 1,477,572 shares. The firm’s market capitalization is $38.00 million. Cytori Therapeutics has a 52-week low of $0.90 and a 52-week high of $2.29. The stock’s 50-day moving average is $1.03 and its 200 day moving average is $1.38.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.05. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $2.32 million. Cytori Therapeutics had a negative return on equity of 177.92% and a negative net margin of 491.71%. The company’s revenue was down 53.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. On average, analysts predict that Cytori Therapeutics will post ($0.90) EPS for the current fiscal year.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. increased its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 10.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 439,679 shares of the biotechnology company’s stock after buying an additional 40,839 shares during the period. Perkins Capital Management Inc. owned 1.87% of Cytori Therapeutics worth $703,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.70% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.